background
persist
childhood
asthma
mainli
atopi
driven
howev
limit
data
exist
risk
factor
childhood
asthma
phenotyp
object
sought
identifi
risk
factor
first
sever
wheez
episod
current
asthma
year
later
separ
atop
nonatop
asthma
method
one
hundr
twentyseven
steroidna
children
first
sever
wheez
episod
emerg
depart
treat
follow
year
primari
outcom
current
asthma
age
year
also
analyz
separ
atop
nonatop
asthma
risk
factor
includ
sensit
viral
caus
main
asthma
risk
factor
analyz
result
studi
entri
median
age
month
interquartil
rang
month
sensit
viru
posit
current
asthma
n
year
divid
atop
n
nonatop
n
asthma
risk
factor
current
atop
asthma
studi
entri
sensit
adjust
odd
ratio
p
eczema
adjust
p
wheez
rhinoviru
adjust
p
risk
factor
nonatop
asthma
first
sever
respiratori
syncyti
virusrhinovirusneg
wheez
episod
adjust
p
first
wheez
episod
age
less
month
adjust
p
parent
smoke
adjust
p
conclus
data
suggest
divers
asthma
phenotyp
mechan
predict
use
simpl
clinic
marker
time
first
sever
wheez
episod
find
import
design
earli
intervent
strategi
secondari
prevent
asthma
j
allergi
clin
immunol
rhinovirusinduc
wheez
atop
characterist
sever
ill
current
import
earli
risk
factor
childhood
asthma
young
hospit
wheez
children
persist
childhood
asthma
mainli
atopi
driven
modifi
asthma
predict
index
api
base
mainli
atop
characterist
use
wide
assess
risk
schoolag
asthma
regardless
asthma
phenotyp
studi
investig
separ
risk
factor
atop
versu
nonatop
asthma
school
age
studi
shown
classic
atop
risk
factor
also
consid
modifi
api
associ
atop
nonatop
asthma
howev
studi
set
heterogen
conduct
birth
cohort
focus
first
wheez
episod
awar
earli
risk
factor
predict
atop
nonatop
asthma
later
childhood
could
also
provid
novel
approach
mechan
underli
childhood
wheez
asthma
phenotyp
simpl
clinic
marker
would
also
offer
way
find
earli
intervent
strategi
prevent
asthma
develop
viral
diagnost
led
good
recognit
rhinovirusinduc
earli
sever
wheez
import
asthma
risk
factor
addit
alreadi
first
wheez
episod
crosssect
studi
link
rhinovirusinduc
wheez
atop
characterist
howev
asthma
risk
associ
rhinovirusinduc
earli
wheez
includ
asthma
predict
indic
limit
way
find
led
suggest
asthma
risk
could
evalu
potenti
modifi
target
pharmacolog
intervent
time
first
wheez
episod
noteworthi
shown
oral
corticosteroid
oc
treatment
decreas
risk
recurr
wheez
asthma
hospit
children
firsttim
wheez
affect
rhinoviru
eczema
aim
studi
assess
risk
factor
first
sever
wheez
episod
corticosteroidna
children
schoolag
age
year
atop
nonatop
asthma
base
previou
literatur
hypothes
first
rhinovirusinduc
wheez
episod
predict
later
atop
asthma
studi
consist
vinku
studi
vinku
mean
wheez
finnish
use
similar
followup
protocol
carri
depart
pediatr
turku
univers
hospit
turku
finland
abbrevi
use
api
asthma
predict
index
ic
inhal
corticosteroid
oc
oral
corticosteroid
odd
ratio
rsv
respiratori
syncyti
viru
recruit
vinku
studi
carri
recruit
studi
carri
origin
aim
studi
evalu
effect
cours
oral
prednisolon
acut
sever
wheez
episod
use
random
control
trial
design
current
longterm
followup
analysi
includ
steroidna
children
age
month
first
sever
wheez
episod
studi
fig
exclus
criteria
use
inhal
corticosteroid
icss
system
corticosteroid
studi
entri
chronic
nonatop
diseas
need
intens
care
studi
approv
ethic
committe
turku
univers
hospit
commenc
obtain
written
inform
consent
guardian
studi
studi
entri
venou
blood
drawn
nasopharyng
aspir
collect
children
random
given
either
oral
prednisolon
placebo
studi
physician
tj
pl
ml
recruit
patient
studi
andor
prospect
follow
schedul
visit
week
month
month
year
year
children
examin
visit
parent
interview
use
standard
questionnair
longterm
visit
see
parent
questionnair
articl
onlin
repositori
wwwjacionlin
org
current
analysi
children
follow
patient
chart
asthma
symptom
medic
laboratori
test
full
followup
period
fig
tabl
addit
children
attend
followup
visit
either
vinku
studi
studi
parent
interview
telephon
age
year
fig
studi
protocol
regist
clinicaltrialsgov
vinku
studi
entri
nasopharyng
aspir
viral
diagnost
drawn
use
standard
procedur
nasopharyng
aspir
analyz
adenoviru
coronavirus
enterovirus
human
bocaviru
human
metapneumoviru
influenza
b
parainfluenza
viru
type
polyomavirus
wu
ki
rhinoviru
type
b
c
respiratori
syncyti
viru
rsv
studi
pcr
use
detect
virus
addit
serolog
done
human
bocaviru
also
vinku
studi
use
cultur
antigen
detect
andor
serolog
adenoviru
enterovirus
human
metapneumoviru
influenza
b
viru
parainfluenza
viru
type
rhinoviru
type
b
rsv
laboratori
studi
studi
entri
age
year
includ
allergenspecif
serum
ige
level
blood
eosinophil
count
measur
use
routin
diagnost
central
laboratori
turku
univers
hospit
longterm
followup
visit
arrang
age
year
fig
flowvolum
spirometri
jaeger
masterscreen
system
jaeger
gmbh
urzburg
germani
vinku
medikro
spirometri
softwar
medikro
oy
kuopio
finland
measur
studi
bronchodilat
test
spirometri
baselin
minut
mg
albuterol
ventolin
administ
mean
inhal
spacer
babyhal
glaxosmithklin
brentford
unit
kingdom
free
run
test
design
measur
bronchial
hyperreact
children
use
spirometri
baselin
minut
exercis
test
regist
index
fev
famili
instruct
withhold
child
regular
asthma
medic
icss
preced
week
withhold
salbutamol
hour
spirometri
test
reschedul
child
ill
take
salbutamol
asthma
symptom
outcom
studi
risk
current
asthma
age
year
analyz
separ
atop
nonatop
asthma
risk
factor
assess
time
first
sever
wheez
episod
tabl
children
given
diagnosi
current
asthma
age
year
met
subsequ
criteria
preced
month
report
patient
chart
doctordiagnos
asthma
need
regular
use
doctorprescrib
asthma
therapi
icss
month
use
ocss
asthma
exacerb
acut
asthma
attack
reliev
repeat
use
bronchodil
andor
hyperreact
spirometri
defin
revers
airflow
obstruct
increas
greater
fev
bronchodilat
test
decreas
greater
exercis
challeng
test
current
atop
asthma
age
year
defin
asthma
laboratoryverifi
sensit
patient
chartand
parentreport
allergi
symptom
tabl
ii
nonatop
asthma
defin
asthma
without
featur
children
remiss
without
asthma
symptom
therapi
within
month
studi
visit
andor
without
hyperreact
spirometri
studi
visit
wheez
episod
defin
sharp
whistl
sound
expiratori
breath
togeth
expiratori
distress
sever
wheez
refer
fact
children
hospit
admit
emerg
depart
tertiari
hospit
sensit
defin
posit
ige
antibodi
result
common
allergen
cutoff
level
kul
codfish
cow
milk
egg
peanut
soybean
wheat
cat
dog
hors
birch
mugwort
timothi
cladosporium
herbarum
dermatophagoid
pteronyssinu
fluoroenzym
immunoassay
cap
feia
phadiatop
combi
phadia
uppsala
sweden
aeroallergen
sensit
defin
ige
antibodi
latter
allergen
eczema
defin
physicianmad
diagnosi
typic
symptom
includ
pruritu
typic
morpholog
chronic
diseas
articl
viral
find
combin
subgroup
accord
viral
etiolog
first
wheez
episod
studi
entri
rhinoviru
group
rhinoviru
alon
virus
rsv
includ
rsv
group
rsv
alon
virus
rhinoviru
exclud
rsvrhinovirusneg
group
virus
virus
found
risk
current
asthma
age
year
assess
use
unadjust
logist
regress
model
baselin
characterist
studi
entri
fisher
exact
test
also
use
cell
count
viral
subgroup
individu
test
dichotom
variabl
rhinoviru
group
vs
group
rsv
group
vs
group
rsvrhinovirusneg
group
vs
group
multivari
analys
adjust
eczema
sensit
parent
smoke
rhinoviru
posit
age
less
month
studi
entri
show
signific
effect
logist
regress
analys
also
done
atop
nonatop
asthma
outcom
separ
time
differ
cohort
recruit
either
also
adjust
cohort
multivari
regress
analys
studi
whether
cohort
signific
model
modifi
magnitud
factor
model
effect
overlap
risk
factor
incid
asthma
age
year
test
x
fisher
exact
test
p
valu
less
regard
statist
signific
analys
made
ibm
spss
softwar
spss
chicago
ill
origin
children
enrol
fig
children
elig
age
year
greater
previou
wheez
ic
oc
treatment
develop
chronic
valu
shown
median
interquartil
rang
number
percentag
subject
defin
ige
antibodi
common
allergen
see
method
section
detail
diseas
enrol
need
intens
care
hospit
children
elig
longterm
followup
nine
children
declin
followup
lost
boy
sensit
rhinoviru
posit
mean
age
month
sd
month
studi
entri
final
elig
children
firsttim
wheez
complet
followup
includ
analysi
children
vinku
studi
studi
children
follow
patient
chart
asthma
symptom
medic
laboratori
test
full
followup
period
addit
children
attend
followup
visit
wherea
rest
follow
patient
chart
n
parent
also
interview
n
fig
tabl
ii
studi
entri
median
age
month
interquartil
rang
month
children
boy
sensit
eczema
viru
posit
tabl
end
followup
period
median
age
year
interquartil
rang
year
tabl
ii
overal
followup
children
given
diagnosi
recurr
wheez
asthma
ever
regular
longterm
asthma
control
therapi
ic
start
thirti
children
asthmat
symptom
remiss
end
followup
boy
sensit
studi
entri
rhinoviru
posit
mean
age
month
rang
month
sd
month
current
asthma
diagnos
children
specifi
atop
asthma
nonatop
asthma
tabl
ii
see
allergi
test
characterist
result
section
articl
onlin
repositori
wwwjacionlineorg
studi
entri
unadjust
risk
factor
list
tabl
current
asthma
sensit
odd
ratio
ci
eczema
ci
first
wheez
episod
age
less
month
ci
p
tabl
iii
multivari
analys
first
wheez
episod
age
less
month
ci
sensit
ci
eczema
ci
parent
smoke
ci
remain
signific
risk
p
tabl
iii
risk
factor
current
atop
asthma
school
age
current
asthma
specifi
atop
nonatop
asthma
unadjust
risk
factor
current
atop
asthma
risk
assess
use
logist
regress
model
unadjust
analys
perform
age
month
versu
age
month
male
versu
femal
sex
eczema
versu
eczema
sensit
allergen
food
aeroallergen
versu
sensit
beo
count
l
greater
versu
beo
count
less
l
parent
asthma
smoke
versu
asthma
smoke
durat
breastfeed
month
greater
versu
less
month
multivari
analys
adjust
age
month
eczema
sensit
parent
smoke
rhinoviru
posit
neg
p
unadjust
analys
na
cell
p
valu
assess
use
fisher
exact
test
cell
count
boldfac
ital
font
indic
statist
signific
beo
blood
eosinophil
count
na
applic
defin
ige
antibodi
common
allergen
see
method
section
detail
na
aeroallergensensit
children
atop
asthma
none
sensit
children
nonatop
asthma
none
rsvrhinovirusneg
children
atop
asthma
knot
includ
model
sensit
studi
entri
tabl
iii
unadjust
risk
factor
nonatop
asthma
rsvrhinovirusneg
etiolog
ci
age
less
month
ci
p
tabl
iii
multivari
analys
rsvrhinovirusneg
etiolog
ci
age
less
month
ci
parent
smoke
ci
remain
signific
risk
p
tabl
iii
multivari
regress
analys
also
adjust
vinku
cohort
signific
multivari
model
atop
nonatop
asthma
modifi
magnitud
risk
factor
incid
current
asthma
increas
cumul
child
concomit
risk
characterist
studi
entri
fig
tabl
iv
incid
asthma
high
eczema
sensit
versu
one
versu
neither
p
respect
sensit
rhinoviru
p
eczema
rhinoviru
p
age
less
month
parent
smoke
age
month
parent
smoke
p
incid
atop
asthma
increas
cumul
concomit
rhinoviru
etiolog
ad
atop
risk
factor
studi
entri
tabl
iv
incid
atop
asthma
high
eczema
sensit
versu
one
versu
neither
p
sensit
rhinoviru
p
eczema
rhinoviru
p
blood
eosinophil
count
l
greater
rhinoviru
p
parent
asthma
rhinoviru
p
fig
tabl
iv
incid
nonatop
asthma
increas
age
less
month
rsvrhinovirusneg
etiolog
versu
one
versu
neither
p
respect
age
less
month
parent
smoke
increas
asthma
incid
versu
one
versu
age
month
parent
smoke
p
tabl
iv
sensit
analys
subset
children
allergi
test
n
trend
direct
main
result
tabl
iii
see
tabl
articl
onlin
repositori
wwwjacionlineorg
sensit
analys
children
without
allergi
test
n
unsuit
statist
analys
sever
cell
count
small
number
outcom
atop
asthma
nonatop
asthma
first
studi
assess
risk
factor
time
first
sever
wheez
episod
atop
nonatop
asthma
phenotyp
age
year
novelti
addit
rhinoviru
etiolog
phenotypebas
risk
assess
show
first
rhinovirusinduc
wheez
alon
togeth
sensit
andor
eczema
predict
atop
nonatop
schoolag
asthma
result
noteworthi
current
schoolag
asthma
risk
children
recurr
wheez
episod
evalu
use
modifi
api
includ
close
atopyrel
characterist
differenti
asthma
phenotyp
risk
factor
nonatop
asthma
first
wheez
age
month
parent
smoke
rsvrhinovirusneg
first
wheez
episod
show
rhinovirusinduc
first
sever
wheez
episod
predict
atop
asthma
school
age
populationbas
studi
previous
earlylif
rhinovirusinduc
wheez
link
schoolag
asthma
birth
cohort
howev
childhood
origin
asthma
australian
birth
cohort
studi
highrisk
cohort
includ
wheez
children
famili
predisposit
atop
asthma
therefor
data
might
reflect
differ
suscept
atop
airway
rhinoviru
infect
contrari
tucson
children
respiratori
studi
nonselect
populationbas
birth
cohort
includ
healthi
infant
investig
observ
children
earlylif
rsvinduc
lower
respiratori
tract
infect
frequent
wheez
school
age
risk
wheez
decreas
insignific
age
year
addit
link
rsv
infect
sensit
previou
studi
differ
childhood
asthma
phenotyp
notic
atop
risk
factor
modifi
api
associ
atop
nonatop
asthma
howev
studi
set
differ
conduct
birth
cohort
focus
first
wheez
episod
includ
older
children
includ
viru
etiolog
wheez
unlik
studi
found
clear
asthmareduc
effect
breastfeed
convers
asthmaincreas
effect
male
sex
show
parent
smoke
predict
nonatop
asthma
contrari
parent
asthma
insignific
univari
model
thu
includ
multivari
model
howev
associ
atop
asthma
concomit
rhinoviru
andor
atop
risk
factor
populationbas
studi
consist
steroidna
firsttim
wheez
children
mainli
hospit
sever
wheez
hospit
treat
emerg
depart
tertiari
hospit
one
third
asthma
year
later
therefor
result
could
adapt
hospit
firsttim
wheez
children
might
provid
new
perspect
estim
futur
asthma
risk
et
al
found
specif
viral
bacteri
risk
factor
schoolag
asthma
henc
suggest
underli
suscept
trigger
instead
specif
trigger
agent
import
asthma
risk
factor
agre
hostdepend
suscept
suggest
trigger
depend
rhinoviru
would
act
import
earli
marker
uncov
underli
suscept
asthma
atop
asthmapron
children
manifest
expiratori
wheez
like
et
al
find
rhinoviru
risk
factor
current
overal
asthma
includ
atop
nonatop
find
signific
risk
factor
atop
asthma
concurr
rsvrhinovirusneg
wheez
associ
nonatop
asthma
probabl
children
rhinovirusposit
wheez
atop
asthma
infant
wheez
might
asthma
risk
marker
often
rhinoviru
induc
particularli
older
children
howev
rhinovirusinduc
wheez
includ
asthmapredict
indic
limit
way
suggest
investig
viru
etiolog
sensit
eczema
statu
especi
combin
might
enabl
asthma
risk
assess
alreadi
time
first
wheez
episod
rhinovirussensit
viral
diagnost
wide
avail
underli
suscept
atop
disord
viral
trigger
might
true
asthma
risk
factor
thu
interplay
sensit
viral
infect
like
involv
childhood
origin
asthma
studi
group
show
chronolog
order
causal
statist
model
ie
earlylif
aeroallergen
sensit
preced
rhinoviru
ill
asthma
howev
slow
develop
aeroallergen
sensit
decreas
valu
asthma
risk
indic
earli
life
wherea
food
sensit
like
develop
earlier
predict
aeroallergen
sensit
futur
asthma
risk
rhinovirusassoci
asthma
risk
explain
increas
suscept
lower
airway
rhinoviru
infect
patient
pronounc
atop
characterist
allergenspecif
ige
sensit
blood
eosinophilia
eczema
matern
atop
eczema
andor
increas
respons
airway
secret
damag
airway
epithelium
decreas
ifnabgl
respons
airway
secret
cell
interact
sensitizationassoci
innat
antivir
pathway
might
lead
sever
viral
ill
alreadi
sensit
children
viral
respiratori
tract
infect
start
sensitizationdepend
cascad
augment
maintain
airway
inflamm
strength
studi
includ
complet
analysi
atop
characterist
viral
etiolog
care
longterm
followup
inclus
rate
high
children
follow
patient
chart
children
attend
studi
visit
age
year
studi
setup
differ
birth
cohort
studi
populationbas
children
experienc
first
sever
wheez
episod
steroid
naiv
receiv
icsoc
treatment
first
wheez
note
shown
ocss
affect
longterm
asthma
outcom
minim
select
bia
includ
children
attend
longterm
studi
visit
peopl
adher
followup
studi
concern
interest
case
asthmat
patient
maxim
object
regard
children
bronchial
hyperreact
spirometri
asthmat
patient
without
proper
pediatricianset
asthma
diagnosi
reflect
reallif
situat
complet
asthma
outcom
minim
heterogen
make
result
generaliz
includ
children
physicianconfirm
wheez
vs
bronchiol
without
wheez
previou
studi
addit
studi
limit
sampl
size
rather
small
exclud
steroidtr
patient
rhinoviru
type
done
conclus
show
sensit
eczema
andor
rhinoviru
etiolog
first
sever
wheez
episod
predict
atop
nonatop
asthma
school
age
contrari
first
wheez
episod
age
month
parent
smoke
rsvrhinovirusneg
first
wheez
episod
predict
nonatop
asthma
school
age
observ
could
provid
novel
approach
mechan
underli
childhood
wheez
asthma
prognost
potenti
differ
therapi
distinct
asthma
phenotyp
would
encourag
find
futur
therapeut
intervent
prevent
asthma
warrant
studi
virolog
atop
statu
worth
assess
earli
children
sever
wheez
recogn
high
asthma
risk
distinguish
risk
asthma
phenotyp
thank
mr
tiina
peromaa
valuabl
help
conduct
exercis
test
tero
vahlberg
msc
contribut
statist
analys
sensit
eczema
rhinoviru
etiolog
first
sever
wheez
episod
predict
atop
asthma
school
age
wherea
rsvrhinovirusneg
etiolog
age
less
month
parent
smoke
predict
nonatop
asthma
data
suggest
divers
asthma
phenotyp
mechan
predict
use
simpl
clinic
marker
time
first
sever
wheez
episod
find
import
design
phenotypebas
therapi
earli
intervent
strategi
asthma
secondari
prevent
